Targeting a neoantigen derived from a common TP53 mutation.

Targeting a neoantigen derived from a common TP53 mutation.
复制标题

DOI:
10.1126/science.abc8697
复制
发表时间:
2021-03-05
期刊:
Science (New York, N.Y.)
影响因子:
--
通讯作者:
Zhou S
Zhou S
中科院分区:
其他
文献类型:
--
作者:
Hsiue EH;Wright KM;Douglass J;Hwang MS;Mog BJ;Pearlman AH;Paul S;DiNapoli SR;Konig MF;Wang Q;Schaefer A;Miller MS;Skora AD;Azurmendi PA;Murphy MB;Liu Q;Watson E;Li Y;Pardoll DM;Bettegowda C;Papadopoulos N;Kinzler KW;Vogelstein B;Gabelli SB;Zhou S

文献摘要

参考文献

被引文献

相似文献

TP53(肿瘤蛋白P53)是最常见的突变的癌症驱动基因,但针对突变的肿瘤抑制基因的药物,如TP53,尚未上市。在这里,我们描述了对最常见的TP53突变(R175H,其中175位的精氨酸被组氨酸取代)与细胞表面常见的人类白细胞抗原-A(HLA-A)等位基因的复合体中高度特异性的抗体的鉴定。我们描述了这种特异性的结构基础及其转化为免疫治疗剂:双特异性单链Diabody。尽管癌细胞表面的P53多肽-人类白细胞抗原复合体密度极低,但这种双特异性抗体在体外和小鼠体内都能有效地激活T细胞,溶解呈递新抗原的癌细胞。从理论上讲,这种方法可以用于靶向含有传统方法难以靶向的突变的癌症。
TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most common TP53 mutation (R175H, in which arginine at position 175 is replaced with histidine) in complex with a common human leukocyte antigen–A (HLA-A) allele on the cell surface. We describe the structural basis of this specificity and its conversion into an immunotherapeutic agent: a bispecific single-chain diabody. Despite the extremely low p53 peptide-HLA complex density on the cancer cell surface, the bispecific antibody effectively activated T cells to lyse cancer cells that presented the neoantigen in vitro and in mice. This approach could in theory be used to target cancers containing mutations that are difficult to target in conventional ways.
实现癌症基因组数据的共同愿景。
DOI: 10.1056/nejmp1607591
发表时间: 2016-09-22
期刊: The New England journal of medicine
影响因子: --
作者:
Grossman RL;Heath AP;Ferretti V;Varmus HE;Lowy DR;Kibbe WA;Staudt LM
通讯作者: Staudt LM
DOI: 10.1158/2326-6066.cir-19-0745
发表时间: 2020-05-01
影响因子: 10.1
作者:
Gejman, Ron S.;Jones, Heather F.;Scheinberg, David A.
通讯作者: Scheinberg, David A.
DOI: 10.1080/2162402x.2016.1168557
发表时间: 2016-06
期刊: Oncoimmunology
影响因子: 7.2
作者:
Cheng M;Santich BH;Xu H;Ahmed M;Huse M;Cheung NK
通讯作者: Cheung NK
DOI: 10.1002/eji.1830110412
发表时间: 1981-01-01
影响因子: 5.4
作者:
BEVERLEY, PCL;CALLARD, RE
通讯作者: CALLARD, RE
DOI: 10.1093/bioinformatics/btv639
发表时间: 2016-02-15
期刊: BIOINFORMATICS
影响因子: 5.8
作者:
Andreatta, Massimo;Nielsen, Morten
通讯作者: Nielsen, Morten